[
1. Alba AC, Bain E, Ng N, Stein M, Brien KO. Complications after Heart Transplantation: Hope for the Best, but Prepare for the Worst. Int J Transplant Res Med. 2016;2(2):2:022. DOI: 10.23937/2572-4045.151002210.23937/2572-4045.1510022
]Search in Google Scholar
[
2. Szymanska S, Grajkowska W, Sobieszczanska-Malek M, Zielinski T, Pyzlak M, Pronicki M. Prevalence of the Quilty effect in endomyocardial biopsy of patients after heart transplantation - from cellular rejection to antibody-mediated rejection? Pol J Pathol. 2016;67(3):216-20. DOI: 10.5114/pjp.2016.6377210.5114/pjp.2016.6377228155969
]Search in Google Scholar
[
3. Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol. 2008;52(8):587-98. DOI: 10.1016/j.jacc.2008.05.02010.1016/j.jacc.2008.05.02018702960
]Search in Google Scholar
[
4. Cipullo R, Finger MA, Rossi Neto JM, Contreras CM, Poltronieri NV, Zamorano Mde M, et al. Vasculitides and eosinophils in endomyocardial biopsies as rejection predictors in heart transplantation. Arq Bras Cardiol. 2011;97(2):163-70. DOI: 10.1590/S0066-782X201100500006910.1590/S0066-782X201100500006921655876
]Search in Google Scholar
[
5. Mozaffari K, Bakhshandeh H, Amin A, Naderi N, Taghavi S, Ojaghi-Haghighi Z, et al. Diagnostic Pitfalls and Challenges in Interpretation of Heart Transplantation Rejection in Endomyocardial Biopsies With Focus on our Experience. Res Cardiovasc Med. 2014;3(1):e13986. DOI: 10.5812/cardiovascmed.1398610.5812/cardiovascmed.13986425374425478529
]Search in Google Scholar
[
6. Zakliczynski M, Nozynski J, Konecka-Mrowka D, Pyka L, Trybunia D, Swierad M, et al. Quilty effect correlates with biopsy-proven acute cellular rejection but does not predict transplanted heart coronary artery vasculopathy. J Heart Lung Transplant. 2009;28(3):255-9. DOI: 10.1016/j.healun.2008.12.01110.1016/j.healun.2008.12.01119285617
]Search in Google Scholar
[
7. Chu KE, Ho EK, de la Torre L, Vasilescu ER, Marboe CC. The relationship of nodular endocardial infiltrates (Quilty lesions) to survival, patient age, anti-HLA antibodies, and coronary artery disease following heart transplantation. Cardiovasc Pathol. 2005;14(4):219-24. DOI: 10.1016/j.carpath.2005.03.00910.1016/j.carpath.2005.03.00916009321
]Search in Google Scholar
[
8. Rigol M, Solanes N, Sionis A, Galvez C, Martorell J, Rojo I, et al. Effects of cyclosporine, tacrolimus and sirolimus on vascular changes related to immune response. J Heart Lung Transplant. 2008;27(4):416-22. DOI: 10.1016/j.healun.2008.01.00610.1016/j.healun.2008.01.00618374878
]Search in Google Scholar
[
9. Joong A, Richmond ME, Stack KO, Rodriguez RJ, McAllister JM, Zuckerman WA, et al. The Quilty Effect in Pediatric Heart Transplant Recipients. The Journal of Heart and Lung Transplantation. 35(4):S75. DOI: 10.1016/j.healun.2016.01.20410.1016/j.healun.2016.01.204
]Search in Google Scholar
[
10. Cho H, Choi JO, Jeon ES, Kim JS. Quilty Lesions in the Endomyocardial Biopsies after Heart Transplantation. J Pathol Transl Med. 2019;53(1):50-6. DOI: 10.4132/jptm.2018.11.3010.4132/jptm.2018.11.30634480130586951
]Search in Google Scholar
[
11. Marboe CC, Billingham M, Eisen H, Deng MC, Baron H, Mehra M, et al. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant. 2005;24(7 Suppl):S219-26. DOI: 10.1016/j.healun.2005.04.00110.1016/j.healun.2005.04.001
]Search in Google Scholar
[
12. Kobashigawa J, Wener L, Johnson J, Currier JW, Yeatman L, Cassem J, et al. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation. J Heart Lung Transplant. 2000;19(6):546-50. DOI: 10.1016/S1053-2498(00)00100-510.1016/S1053-2498(00)00100-5
]Search in Google Scholar
[
13. Minicucci MF, Zornoff LAM. VEGFR-2: One of Pioglitazone’s Signaling Pathways in the Heart. Arq Bras Cardiol. 2018;111(2):170-1. DOI: 10.5935/abc.2018014710.5935/abc.20180147
]Search in Google Scholar
[
14. Waltenberger J, Kranz A, Beyer M. Neovascularization in the human heart is associated with expression of VEGF-A and its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2). Results from cardiomyopexy in ischemic cardiomyopathy. Angiogenesis. 1999;3(4):345-51. DOI: 10.1023/A:102658590039810.1023/A:1026585900398
]Search in Google Scholar
[
15. Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ. Cardiac allograft vasculopathy: a review. Can J Surg. 2005;48(4):319-27.
]Search in Google Scholar
[
16. Patel JK, Kobashigawa JA. Cardiac transplant experience with cyclosporine. Transplant Proc. 2004;36(2 Suppl):323S-30S. DOI: 10.1016/j.transproceed.2004.01.03910.1016/j.transproceed.2004.01.039
]Search in Google Scholar
[
17. Maravić-Stojković V, Stojković B, Perić M. Modern immunosuppressive agents after heart transplantation. Curr Trend Cardiol. 2017;1(2):41-8.
]Search in Google Scholar
[
18. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6(6):1377-86. DOI: 10.1111/j.1600-6143.2006.01290.x10.1111/j.1600-6143.2006.01290.x
]Search in Google Scholar
[
19. Lopez Garcia-Gallo C, Garcia Fadul C, Laporta R, Portero F, Millan I, Ussetti P. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience. Ann Transplant. 2015;20:661-6. DOI: 10.12659/AOT.89469410.12659/AOT.894694
]Search in Google Scholar
[
20. Luckraz H, Charman SC, Wreghitt T, Wallwork J, Parameshwar J, Large SR. Does cytomegalovirus status influence acute and chronic rejection in heart transplantation during the ganciclovir prophylaxis era? J Heart Lung Transplant. 2003;22(9):1023-7. DOI: 10.1016/S1053-2498(02)01185-310.1016/S1053-2498(02)01185-3
]Search in Google Scholar
[
21. Bolovan-Fritts CA, Trout RN, Spector SA. High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage. Blood. 2007;110(6):1857-63. DOI: 10.1182/blood-2007-03-07888110.1182/blood-2007-03-078881197635717519388
]Search in Google Scholar
[
22. Frantzeskaki FG, Karampi ES, Kottaridi C, Alepaki M, Routsi C, Tzanela M, et al. Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers. J Crit Care. 2015;30(2):276-81. DOI: 10.1016/j.jcrc.2014.10.00210.1016/j.jcrc.2014.10.00225457114
]Search in Google Scholar
[
23. Liu XF, Wang X, Yan S, Zhang Z, Abecassis M, Hummel M. Epigenetic control of cytomegalovirus latency and reactivation. Viruses. 2013;5(5):1325-45. DOI: 10.3390/v505132510.3390/v5051325371231023698401
]Search in Google Scholar
[
24. Barge-Caballero E, Almenar-Bonet L, Crespo-Leiro MG, Brossa-Loidi V, Rangel-Sousa D, Gomez-Bueno M, et al. Preoperative Toxoplasma gondii serostatus does not affect long-term survival of cardiac transplant recipients. Analysis of the Spanish Heart Transplantation Registry. Int J Cardiol. 2018;250:183-7. DOI: 10.1016/j.ijcard.2017.09.21510.1016/j.ijcard.2017.09.21529031991
]Search in Google Scholar
[
25. Kittleson MM, Kobashigawa JA. Toxoplasma gondii exposure in the heart transplant recipient: good, bad, or indifferent? Transplantation. 2013;96(12):1025. DOI: 10.1097/TP.0b013e3182a9276910.1097/TP.0b013e3182a9276924092388
]Search in Google Scholar
[
26. Vitrone M, Iossa D, Rinaldi L, Pafundi PC, Molaro R, Parrella A, et al. Hepatitis B virus reactivation after heart transplant: Incidence and clinical impact. J Clin Virol. 2017;96:54-9. DOI: 10.1016/j.jcv.2017.09.01110.1016/j.jcv.2017.09.01128964958
]Search in Google Scholar
[
27. Iossa D, Vitrone M, Liotti A, Portella G, Durante-Mangoni E, Zampino R. Hepatitis B core-related antigen to detect hepatitis B virus (HBV) reactivation in heart transplant recipients with past HBV infection: A pilot study. Clin Transplant. 2019;33(6):e13574. DOI: 10.1111/ctr.1357410.1111/ctr.1357431013373
]Search in Google Scholar